Vaughan R B, Angus P W, Chin-Dusting J P F
Victorian Liver Transplant Unit, Austin and Repatriation Medical Centre, Studley Rd, Heidelberg, Melbourne, VIC 3084, Australia.
Gut. 2003 Oct;52(10):1505-10. doi: 10.1136/gut.52.10.1505.
There is evidence that dampened responses to endogenous vasoconstrictors contribute to the hyperdynamic circulation that is characteristic of advanced cirrhosis. The aim of this study was to determine whether there is an altered vascular responsiveness to the endothelium derived constricting factor endothelin-1 (ET-1) in patients with decompensated chronic liver disease which might contribute to this abnormal circulatory state, and whether normal endothelin responses are restored following liver transplantation.
Using forearm plethysmography, we studied the vascular response to an intra-arterial ET-1 infusion in six patients with end stage cirrhosis, before and after liver transplantation, compared with six normal control subjects. Responses to the selective endothelin A (ET(A)) receptor subtype antagonist, BQ123, were also examined.
The forearm vessels of patients with cirrhosis vasodilated in response to ET-1 infusion while in healthy controls a marked vasoconstriction response was observed (p<0.0001, area under the curve time-blood flow was normal compared with the cirrhosis groups, ANOVA). Prior to commencement of liver transplant surgery, cirrhotic patients were confirmed to have a hyperdynamic circulation with a high cardiac index (4.07 (0.23) l/min/m(2) (normal range 2.8-3.6 l/min/m(2))) and low systemic vascular resistance index (1284 (115) dynxs/cm(5)/m(2) (normal range 1760-2600 dynxs/cm(5)/m(2))). Following transplantation, normal vasoconstrictor responses to ET-1 were restored. Responses to BQ123 were not different in patients with advanced cirrhosis compared with controls.
In patients with end stage cirrhosis, ET-1 produces vasodilatation at a dose that causes marked vasoconstriction in normal control subjects. This effect is not attributable to impairment of ET(A) receptor responses. Our findings suggest that altered endothelin responses may contribute to the generalised dilatation of the circulation that occurs in patients with advanced liver disease.
有证据表明,内源性血管收缩剂反应减弱导致了晚期肝硬化特征性的高动力循环。本研究旨在确定失代偿期慢性肝病患者对内皮素-1(ET-1)这种内皮衍生收缩因子的血管反应性是否改变,这可能导致这种异常循环状态,以及肝移植后正常内皮素反应是否恢复。
使用前臂体积描记法,我们研究了6例终末期肝硬化患者肝移植前后动脉内输注ET-1时的血管反应,并与6名正常对照者进行比较。还检测了对选择性内皮素A(ET(A))受体亚型拮抗剂BQ123的反应。
肝硬化患者的前臂血管在输注ET-1时出现血管舒张,而健康对照者则观察到明显的血管收缩反应(p<0.0001,曲线下面积-时间-血流与肝硬化组相比正常,方差分析)。在肝移植手术开始前,肝硬化患者被证实存在高动力循环,心脏指数高(4.07(0.23)升/分钟/平方米(正常范围2.8 - 3.6升/分钟/平方米)),全身血管阻力指数低(1284(115)达因·秒/厘米⁵/平方米(正常范围1760 - 2600达因·秒/厘米⁵/平方米))。移植后,对ET-1的正常血管收缩反应得以恢复。晚期肝硬化患者对BQ123的反应与对照组无差异。
在终末期肝硬化患者中,ET-1在正常对照者中引起明显血管收缩的剂量下产生血管舒张作用。这种效应不归因于ET(A)受体反应受损。我们的研究结果表明,内皮素反应改变可能导致晚期肝病患者出现的全身循环扩张。